BHVNBiohaven Ltd.同业对比
Biohaven Ltd. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BHVN本股 | $2.4B#8 | — | — | — | — | 12.7%#6 | — | — | — | — | 5.1%#11 | — |
| IRON | $3.1B#1 | — | 4.8x#9 | — | — | -94.0%#13 | — | -32.9%#8 | -39.0%#6 | — | -4.1%#13 | — |
| BHC | $3.0B#2 | — | — | 0.3x#1 | 6.7%#8 | 441.3%#1 | 17.7%#3 | — | 3.7%#3 | — | 33.2%#6 | 11.7%#1 |
| IDYA | $3.0B#3 | — | 2.8x#4 | 13.8x#5 | 3024.4%#2 | 58.6%#3 | -72.8%#5 | -10.4%#3 | — | — | -0.2%#12 | — |
| VRDN | $2.8B#4 | — | 4.3x#6 | 40.2x#9 | 23359.9%#1 | -26.9%#10 | -512.9%#10 | -51.7%#10 | -54.5%#7 | — | 8.6%#10 | — |
| NRIX | $2.8B#5 | 10.6x#1 | 2.9x#5 | 33.6x#8 | 54.0%#4 | -36.6%#11 | -340.2%#9 | -27.3%#7 | — | — | 104.8%#3 | — |
| MBX | $2.7B#6 | — | 6.5x#12 | — | — | -40.5%#12 | — | -21.2%#6 | — | — | 166.7%#1 | — |
| RCUS | $2.4B#7 | — | 5.2x#10 | 73.0x#11 | -35.3%#12 | -24.7%#9 | -1169.7%#11 | -76.1%#13 | -93.0%#10 | — | -7.0%#14 | — |
| PBH | $2.3B#9 | 13.9x#3 | 1.2x#2 | 2.2x#3 | -4.3%#10 | -11.3%#8 | 28.4%#1 | 9.9%#2 | 5.9%#2 | 4#1 | -18.2%#16 | — |
| IMNM | $2.3B#10 | — | 4.4x#7 | 332.7x#12 | -23.2%#11 | 27.5%#5 | -3228.8%#12 | -40.4%#9 | -72.8%#9 | — | 19.4%#8 | — |
| XNCR | $2.3B#11 | — | 4.5x#8 | 18.2x#6 | 13.7%#7 | 60.5%#2 | -141.4%#8 | -18.3%#4 | -31.5%#5 | — | 120.4%#2 | — |
| VERA | $2.2B#12 | — | 5.4x#11 | — | — | -96.9%#14 | — | -73.5%#12 | -72.7%#8 | — | 18.5%#9 | — |
| PVLA | $2.2B#13 | — | 10.2x#13 | 51.6x#10 | 65.3%#3 | -139.3%#15 | -90.2%#7 | -19.2%#5 | — | — | 99.0%#4 | — |
| PRGO | $2.2B#14 | — | 0.9x#1 | 0.5x#2 | -2.8%#9 | -729.7%#16 | -26.4%#4 | -56.7%#11 | -20.9%#4 | 4#1 | -18.0%#15 | 7.3%#2 |
| HRMY | $2.2B#15 | 12.0x#2 | 2.2x#3 | 2.5x#4 | 21.5%#6 | 9.1%#7 | 24.0%#2 | 15.9%#1 | 25.5%#1 | 4#1 | 26.2%#7 | — |
| ZYME | $2.1B#16 | — | 26.6x#14 | 20.2x#7 | 38.9%#5 | 33.9%#4 | -87.3%#6 | -100.9%#14 | — | — | 59.5%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议